Application 021018
- Type
- BLA
- Sponsor
- LILLY
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | HUMALOG MIX 50/50 | INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT | INJECTABLE;INJECTION | 50 UNITS/ML;50 UNITS/ML | No | No |
| 002 | HUMALOG MIX 50/50 KWIKPEN | INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT | INJECTABLE;INJECTION | 50 UNITS/ML;50 UNITS/ML | No | No |
| 003 | HUMALOG MIX 50/50 PEN | INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT | INJECTABLE;INJECTION | 50 UNITS/ML;50 UNITS/ML | No | No |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | BLA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | BLA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | BLA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-7512 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | BLA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | BLA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | BLA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
| 0002-8798 | Humalog | Insulin lispro | Eli Lilly and Company | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 74878 | SUPPL | 2023-07-24 |
| 74872 | SUPPL | 2023-07-24 |
| 66379 | APPL | 2020-03-23 |
| 60947 | SUPPL | 2020-03-23 |
| 60946 | SUPPL | 2020-03-23 |
| 60880 | SUPPL | 2020-03-23 |
| 60879 | SUPPL | 2020-03-23 |
| 57667 | SUPPL | 2020-03-23 |
| 55757 | SUPPL | 2020-03-23 |
| 55756 | SUPPL | 2020-03-23 |
| 55627 | SUPPL | 2020-03-23 |
| 55626 | SUPPL | 2020-03-23 |
| 46789 | SUPPL | 2020-03-23 |
| 46763 | SUPPL | 2020-03-23 |
| 41881 | ORIG | 2020-03-23 |
| 35910 | SUPPL | 2020-03-23 |
| 35909 | SUPPL | 2020-03-23 |
| 35908 | SUPPL | 2020-03-23 |
| 35907 | SUPPL | 2020-03-23 |
| 35906 | SUPPL | 2020-03-23 |
| 35905 | SUPPL | 2020-03-23 |
| 26513 | SUPPL | 2020-03-23 |
| 26512 | SUPPL | 2020-03-23 |
| 26511 | SUPPL | 2020-03-23 |
| 26510 | SUPPL | 2020-03-23 |
| 26509 | SUPPL | 2020-03-23 |
| 26508 | SUPPL | 2020-03-23 |
| 26507 | SUPPL | 2020-03-23 |
| 26506 | ORIG | 2020-03-23 |
| 14189 | SUPPL | 2020-03-23 |
| 14188 | SUPPL | 2020-03-23 |
| 14187 | ORIG | 2020-03-23 |
| 4072 | SUPPL | 2020-03-23 |
| 4071 | SUPPL | 2020-03-23 |